BRPI0806945A2 - Formas polimórficas de um inibidor macrocíclico de hcv - Google Patents

Formas polimórficas de um inibidor macrocíclico de hcv

Info

Publication number
BRPI0806945A2
BRPI0806945A2 BRPI0806945-0A2A BRPI0806945A BRPI0806945A2 BR PI0806945 A2 BRPI0806945 A2 BR PI0806945A2 BR PI0806945 A BRPI0806945 A BR PI0806945A BR PI0806945 A2 BRPI0806945 A2 BR PI0806945A2
Authority
BR
Brazil
Prior art keywords
hcv
polymorphic forms
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
BRPI0806945-0A2A
Other languages
English (en)
Inventor
Sigrid Carl Maria Stokbroekx
Carina Leys
Kelly Ann Swinney
Stijn Wuyts
Andras Horvath
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0806945(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0806945A2 publication Critical patent/BRPI0806945A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0806945-0A2A 2007-02-01 2008-02-01 Formas polimórficas de um inibidor macrocíclico de hcv BRPI0806945A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01
PCT/EP2008/051268 WO2008092954A2 (en) 2007-02-01 2008-02-01 Polymorphic forms of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number Publication Date
BRPI0806945A2 true BRPI0806945A2 (pt) 2014-05-06

Family

ID=38229348

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806945-0A2A BRPI0806945A2 (pt) 2007-02-01 2008-02-01 Formas polimórficas de um inibidor macrocíclico de hcv

Country Status (25)

Country Link
US (1) US8143402B2 (pt)
EP (1) EP2118098B1 (pt)
JP (1) JP5523110B2 (pt)
KR (1) KR101580226B1 (pt)
CN (3) CN101589040A (pt)
AR (2) AR065136A1 (pt)
AU (1) AU2008209696B2 (pt)
BR (1) BRPI0806945A2 (pt)
CA (1) CA2677170C (pt)
CL (1) CL2008000321A1 (pt)
CY (1) CY1116339T1 (pt)
DK (1) DK2118098T3 (pt)
ES (1) ES2524784T3 (pt)
HK (1) HK1205125A1 (pt)
HR (1) HRP20141137T1 (pt)
IL (1) IL199215A (pt)
MX (1) MX2009008275A (pt)
NZ (1) NZ577568A (pt)
PL (1) PL2118098T3 (pt)
PT (1) PT2118098E (pt)
RU (1) RU2533830C2 (pt)
SI (1) SI2118098T1 (pt)
TW (1) TWI423968B (pt)
WO (1) WO2008092954A2 (pt)
ZA (1) ZA200905377B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
LT2401272T (lt) * 2009-02-27 2017-03-27 Janssen Pharmaceuticals, Inc. Hcv makrociklinio slopiklio amorfinė druska
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
PL2528922T3 (pl) 2010-01-27 2018-01-31 Ab Pharma Ltd Związki poliheterocykliczne jako inhibitory hcv
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20140044759A1 (en) * 2011-05-04 2014-02-13 Dimitrios Zarkadas Drug substances, pharmaceutical compositions and methods for preparing the same
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
WO2013037705A2 (en) * 2011-09-16 2013-03-21 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015109925A1 (zh) * 2014-01-21 2015-07-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
BRPI0414814A (pt) * 2003-09-26 2006-11-14 Schering Corp inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
HRP20130098T1 (hr) * 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
BRPI0506948B1 (pt) * 2004-01-30 2018-09-18 Medivir Ab inibidores de serina protease ns-3 de hcv
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
WO2008092954A3 (en) 2008-10-02
PL2118098T3 (pl) 2015-03-31
CN105037347B (zh) 2018-06-01
CL2008000321A1 (es) 2008-08-22
AR108819A2 (es) 2018-09-26
HK1205125A1 (en) 2015-12-11
NZ577568A (en) 2012-02-24
ES2524784T3 (es) 2014-12-12
TW200846347A (en) 2008-12-01
EP2118098A2 (en) 2009-11-18
TWI423968B (zh) 2014-01-21
US20100029715A1 (en) 2010-02-04
CY1116339T1 (el) 2017-02-08
CN104230918A (zh) 2014-12-24
HRP20141137T1 (hr) 2015-01-30
AU2008209696A1 (en) 2008-08-07
SI2118098T1 (sl) 2015-01-30
CA2677170C (en) 2017-04-18
KR101580226B1 (ko) 2015-12-24
RU2533830C2 (ru) 2014-11-20
WO2008092954A2 (en) 2008-08-07
CN101589040A (zh) 2009-11-25
HK1137438A1 (en) 2010-07-30
CN105037347A (zh) 2015-11-11
DK2118098T3 (en) 2014-12-08
ZA200905377B (en) 2010-10-27
JP5523110B2 (ja) 2014-06-18
WO2008092954A8 (en) 2009-12-23
CN104230918B (zh) 2018-01-26
MX2009008275A (es) 2009-08-12
CA2677170A1 (en) 2008-08-07
KR20090115929A (ko) 2009-11-10
AU2008209696B2 (en) 2013-05-09
EP2118098B1 (en) 2014-09-24
IL199215A (en) 2015-10-29
JP2010517971A (ja) 2010-05-27
US8143402B2 (en) 2012-03-27
PT2118098E (pt) 2014-12-09
AR065136A1 (es) 2009-05-20
RU2009132660A (ru) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI0806945A2 (pt) Formas polimórficas de um inibidor macrocíclico de hcv
BRPI0807087A2 (pt) Inibidores de hcv macrocíclicos substituídos de pirimidina
BRPI0807482A2 (pt) Fenilcarbamatos macrocíclicos inibidores de hcv
EP2055698A4 (en) CHROME LINK
DK2097402T3 (da) Makrocykliske inhibitorer af hepatitis c-virus
NO347644B1 (no) Polymorfer
DK2084175T3 (da) HCV nucleosidinhibitor
EP2189988A4 (en) Shift register
DE602007006415D1 (de) Schieberegister
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK2373172T3 (da) Hcv-ns5a-hæmmere
BRPI0914760A2 (pt) torneira expandida
FR2898073B3 (fr) Jante
BRPI0718874A2 (pt) Compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
DK1996710T3 (da) Rifaximin-præparat mod rektal dysfunktion
BRPI0923184A2 (pt) inibidores de hcv ns3 protease
CR10562A (es) Nuevos derivados de piridazina
DK2111555T3 (da) Diagnosticering af præeklampsi
BRPI0712902A2 (pt) compostos orgânicos
BRPI0820677A2 (pt) Misturas de compostos pesticidas
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0923393A2 (pt) Processos e intermediários para preparar um inibidor de protease de hcv macrocíclico
BRPI0821567A2 (pt) Misturas de compostos pesticidas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]